Versant Capital Management’s Humana HUM Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $235K | Buy |
591
+300
| +103% | +$85.4K | 0.02% | 561 |
|
|
2026
Q1 | $50.5K | Sell |
291
-378
| -57% | -$77.5K | 0.01% | 1240 |
|
|
2025
Q4 | $171K | Sell |
669
-313
| -32% | -$82.1K | 0.02% | 545 |
|
|
2025
Q3 | $255K | Buy |
982
+370
| +60% | +$97.3K | 0.03% | 400 |
|
|
2025
Q2 | $150K | Buy |
612
+159
| +35% | +$39.6K | 0.02% | 529 |
|
|
2025
Q1 | $120K | Buy |
453
+66
| +17% | +$17.9K | 0.02% | 569 |
|
|
2024
Q4 | $98.2K | Buy |
387
+52
| +16% | +$13.9K | 0.02% | 320 |
|
|
2024
Q3 | $106K | Sell |
335
-32
| -9% | -$11.4K | 0.02% | 230 |
|
|
2024
Q2 | $137K | Buy |
367
+161
| +78% | +$54.4K | 0.03% | 174 |
|
|
2024
Q1 | $71.4K | Buy |
206
+17
| +9% | +$6.44K | 0.02% | 232 |
|
|
2023
Q4 | $86.5K | Sell |
189
-2
| -1% | -$986 | 0.03% | 209 |
|
|
2023
Q3 | $92.9K | Sell |
191
-8
| -4% | -$3.76K | 0.03% | 188 |
|
|
2023
Q2 | $89K | Buy |
199
+8
| +4% | +$4.03K | 0.03% | 193 |
|
|
2023
Q1 | $92.7K | Buy |
191
+3
| +2% | +$1.48K | 0.03% | 181 |
|
|
2022
Q4 | $96.3K | Sell |
188
-10
| -5% | -$5.26K | 0.03% | 157 |
|
|
2022
Q3 | $96K | Hold |
198
| – | – | 0.04% | 153 |
|
|
2022
Q2 | $93K | Hold |
198
| – | – | 0.03% | 156 |
|
|
2022
Q1 | $86K | Hold |
198
| – | – | 0.03% | 181 |
|
|
2021
Q4 | $92K | Hold |
198
| – | – | 0.03% | 166 |
|
|
2021
Q3 | $77K | Sell |
198
-6
| -3% | -$2.55K | 0.03% | 173 |
|
|
2021
Q2 | $90K | Sell |
204
-1
| -0.5% | -$437 | 0.03% | 153 |
|
|
2021
Q1 | $86K | Sell |
205
-5
| -2% | -$2K | 0.03% | 160 |
|
|
2020
Q4 | $86K | Hold |
210
| – | – | 0.03% | 156 |
|
|
2020
Q3 | $86K | Hold |
210
| – | – | 0.04% | 148 |
|
|
2020
Q2 | $81K | Hold |
210
| – | – | 0.04% | 147 |
|
|
2020
Q1 | $65K | Hold |
210
| – | – | 0.03% | 151 |
|
|
2019
Q4 | $76K | Sell |
210
-3
| -1% | -$952 | 0.04% | 149 |
|
|
2019
Q3 | $54K | Buy |
213
+5
| +2% | +$1.4K | 0.03% | 204 |
|
|
2019
Q2 | $55K | Sell |
208
-25
| -11% | -$6.34K | 0.03% | 203 |
|
|
2019
Q1 | $61K | Sell |
233
-3
| -1% | -$865 | 0.03% | 228 |
|
|
2018
Q4 | $67K | Hold |
236
| – | – | 0.03% | 188 |
|
|
2018
Q3 | $79K | Sell |
236
-22
| -9% | -$7.15K | 0.03% | 183 |
|
|
2018
Q2 | $76K | Hold |
258
| – | – | 0.03% | 197 |
|
|
2018
Q1 | $69K | Sell |
258
-14
| -5% | -$3.79K | 0.03% | 208 |
|
|
2017
Q4 | $67K | Hold |
272
| – | – | 0.03% | 227 |
|
|
2017
Q3 | $66K | Hold |
272
| – | – | 0.04% | 200 |
|
|
2017
Q2 | $65K | Hold |
272
| – | – | 0.04% | 196 |
|
|
2017
Q1 | $56K | Hold |
272
| – | – | 0.03% | 238 |
|
|
2016
Q4 | $55K | Sell |
272
-2
| -0.7% | -$381 | 0.03% | 251 |
|
|
2016
Q3 | $48K | Buy |
274
+6
| +2% | +$1.04K | 0.03% | 267 |
|
|
2016
Q2 | $48K | Buy |
268
+11
| +4% | +$1.95K | 0.03% | 247 |
|
|
2016
Q1 | $47K | Sell |
257
-1
| -0.4% | -$173 | 0.03% | 248 |
|
|
2015
Q4 | $46K | Buy |
+258
| New | +$45.3K | 0.03% | 245 |
|
Other funds holding HUM
HGIM
PL
FFM
CNB
WC
II
COPPSERS
P
Versant Capital Management's HUM Position: Q2 2026 in Review
Versant Capital Management increased its Humana (HUM) stake by 103% in Q2 2026, buying an estimated $85.4K and bringing the position to 591 shares worth $235K. The position accounts for 0.02% of the portfolio, ranked #561.
Versant Capital Management first reported a position in HUM in Q4 2015 and has held it in 43 quarters since. The position peaked at $255K in Q3 2025. 181 funds tracked by Wall St. Rank hold HUM as of Q2 2026.
- Versant Capital Management held 591 shares of Humana worth $235K as of Q2 2026.
- Versant Capital Management bought 300 Humana shares in Q2 2026, an estimated $85.4K.
- Humana made up 0.02% of Versant Capital Management's portfolio in Q2 2026, its #561 holding.
- Versant Capital Management first reported a position in Humana in Q4 2015 and has held it in 43 quarters since.
- Versant Capital Management's Humana position peaked at $255K in Q3 2025.
- 181 funds tracked by Wall St. Rank held Humana as of Q2 2026.
Based on Versant Capital Management's 13F filing for Q2 2026, filed 2 Jul 2026.